Please find attached Clarification letter in respect of Outcome of Board meeting held on 08.08.2026 and submitted on 08.08.2026 for approval of Preferential issue of Shares

To, Date: - 10th August, 2026 Corporate Relation Departments, BSE Limited, 25" Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 544529; ISIN: INE15XJ01010 Dear Sir, Sub: - Clarification regarding typographical error in Outcome of the Board Meeting Dated 08.08.2026 This is with reference to the Outcome of the Meeting of the Board of Directors of by APTUS PHARMA LIMITED held on Saturday, August 08, 2026, submitted to BSE Limited on August 08, 2026. We wish to bring to your kind attention that, due to an inadvertent typographical error in the opening paragraph of the said letter, the venue of the meeting was stated as “the registered o(cid:431)ice of the Company” instead of “the Head O(cid:431)ice of the Company situated at RK Trade Tower, Wing A, O(cid:431)ice Nos. 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India – 360006.” Accordingly, the reference to “the registered o(cid:431)ice of the Company” in the opening paragraph of the said letter shall be read as follows: “the Head O(cid:431)ice of the Company situated at RK Trade Tower, Wing A, O(cid:431)ice Nos. 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India – 360006.” We further wish to clarify that the annexure referred to as “Annexure A” under Point No. 1 of the said letter was inadvertently titled “Annexure 1” in the annexure itself. Accordingly, the title “Annexure 1” shall be read as “Annexure A.” We hereby confirm that the aforesaid errors are purely typographical in nature and that there is no change in the substance, decision or outcome of the resolution(s) passed or matter(s) considered by the Board of Directors at the said meeting. We request you to kindly take this clarification on record and read the aforesaid disclosure with the corrections stated above. We regret the inadvertent typographical errors and assure you that due care will be exercised in future disclosures. Thanking You FOR, APTUS PHARMA LIMITED TEJAS HATHI MANAGING DIRECTOR DIN: 03151221